首页> 外文期刊>American Journal of Translational Research >Progress and prospect of mesenchymal stem cell-based therapy in atherosclerosis
【24h】

Progress and prospect of mesenchymal stem cell-based therapy in atherosclerosis

机译:间充质干细胞治疗动脉粥样硬化的研究进展与展望

获取原文
           

摘要

Atherosclerosis is a chronic inflammatory disease of the arterial intima, occurring usually in the aged populations who are suffering from hypertension, dyslipidemia and diabetes for a long time. Research on atherosclerosis has shown that macrophage foam cell formation, inflammation, dyslipidemia and immune cells infiltration are all involved in regulating the onset and progression of atherosclerosis. Mesenchymal stem cells (MSCs) originated from different kinds of tissue are a group of cells possessing well-established self-renewal and multipotent differentiation properties as well as immunomodulatory and anti-inflammatory roles. Recent studies have displayed their dyslipidemia regulation functions. Transplantation of MSCs to atherosclerotic patients might be a new multifactorial therapeutic strategy to improve atherosclerosis. This review updates the advancement on MSCs and atherosclerosis.
机译:动脉粥样硬化是动脉内膜的慢性炎性疾病,通常发生在长期患有高血压,血脂异常和糖尿病的老年人群中。对动脉粥样硬化的研究表明,巨噬细胞泡沫细胞的形成,炎症,血脂异常和免疫细胞浸润均与调节动脉粥样硬化的发生和发展有关。源自不同组织的间充质干细胞(MSC)是一组具有完善的自我更新和多能分化特性以及免疫调节和抗炎作用的细胞。最近的研究表明其血脂异常调节功能。 MSCs移植到动脉粥样硬化患者可能是改善动脉粥样硬化的一种新的多因素治疗策略。这篇综述更新了MSC和动脉粥样硬化的研究进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号